These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18219801

  • 1. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
    [No Abstract] [Full Text] [Related]

  • 2. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI, Wittkowsky AK, Hylek EM, Walker MB.
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Warfarin and pharmacogenomic testing: what would Pascal do?
    Teagarden JR.
    Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M, Reynolds KK, Valdes R, Linder MW.
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [Abstract] [Full Text] [Related]

  • 9. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM, Spreafico M, Peyvandi F.
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
    Carlquist JF, Anderson JL.
    Circulation; 2011 Dec 06; 124(23):2554-9. PubMed ID: 22144632
    [No Abstract] [Full Text] [Related]

  • 13. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH, Tsui KK, Wong RS, Cheng G.
    Clin Pharmacol Ther; 2009 Nov 06; 86(5):540-7. PubMed ID: 19571807
    [Abstract] [Full Text] [Related]

  • 14. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy?
    Goto S.
    Circ J; 2010 May 06; 74(5):850-1. PubMed ID: 20424335
    [No Abstract] [Full Text] [Related]

  • 15. Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice.
    van der Zee SA, Halperin JL.
    Nat Rev Cardiol; 2010 Oct 06; 7(10):549-50. PubMed ID: 20865027
    [No Abstract] [Full Text] [Related]

  • 16. Genetic factors for warfarin dose prediction.
    Lippi G, Salvagno GL, Guidi GC.
    Clin Chem; 2007 Sep 06; 53(9):1721-2. PubMed ID: 17712016
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T, Tanabe T, Ohno M, Tougou K, Fujio Y, Azuma J, Yamamoto I, Takeda A.
    Clin Pharmacol Ther; 2006 Nov 06; 80(5):553-4. PubMed ID: 17112813
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.